Macular Degeneration Treatment Market - Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Macular Degeneration Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

The global macular degeneration treatment market was valued at USD 7,755 million in 2020, and it is expected to reach USD 11,492 million by 2026, registering a CAGR of 6.9% during the period of 2021-2026.

The COVID-19 pandemic had a potential economic impact and implications on most of the sectors, including the pharmaceutical and biotech industries. One of the major driving factors for the macular degeneration treatment market is the aging population. However, due to the COVID - 19 pandemic, it is becoming more apparent that older adults and people with underlying health conditions are most susceptible to the illness.

Furthermore, the impact of COVID-19 on macular degeneration treatment market was negative because the outbreak of COVID-19 in 2020 has resulted in the reduction of attendance at scheduled clinic visits and intravitreal injections (IVI).

The major factors attributing to the growth of the macular degeneration treatment market are, increasing burden of retinal disorders, upsurge in geriatric population and increase in research and development investments.

According to a research article by Jeany Q Li et al., published in British Journal of Ophthalmology August 2020, in Europe, age-related macular degeneration (AMD) is the main cause of visual impairment and blindness. About 67 million people in the Europe are affected by any age-related macular degeneration (AMD) and, due to population ageing, this number is expected to increase by 15% until 2050. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to the market growth.

Furthermore, the increasing research and development investments and rising approvals for the new drugs are other major factors for the market growth. For instance, in September 2020, the United Food and Drug Administration (FDA) granted the Fast-Track designation to GT005, an investigational, one-time, AAV-based gene therapy for the treatment of geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD). GT005 was developed by Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company.

However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints to the growth of the market.

Key Market Trends

Wet Age-related Macular Degeneration is Expected to Hold Significant Market Share Over the Forecast Period.

The rising number of geriatric population all over the world is creating the high-level demand in wet macular degeneration market. For instance, For instance, as per United Nations World Ageing 2019 report, majority share of the older population is contributed by Eastern and South Eastern Asia followed by Europe and North America. Eastern and South Eastern Asia is also expected to observe a largest increase by about 312 million in the coming years as compared to any other regions.

Furthermore, in 2019, there were around 200 million people who were 65 years and above in North America and Europe regions. Above statistics represent the high demand for the products for the treatment of wet macular degeneration globally in coming future.

Competitive Landscape

The Macular Degeneration Treatment market is moderately competitive. However, with product innovations, mid-size to small companies are increasing their market presence by introducing new products. Some of the companies which include F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Pfizer Inc., and others.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Burden of Retinal Disorders

4.2.2 Upsurge in Geriatric Population

4.2.3 Increase in Research and Development Investments

4.3 Market Restraints

4.3.1 Increasing Use of Off-label Drugs

4.3.2 Lack of Awareness regarding AMD

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Type

5.1.1 Dry Age-related Macular Degeneration

5.1.2 Wet Age-related Macular Degeneration

5.2 By Stage of Disease

5.2.1 Early-stage AMD

5.2.2 Intermediate AMD

5.2.3 Late-stage AMD

5.3 By Route of Administration

5.3.1 Intravenous Route

5.3.2 Intravitreal Route

5.4 By Sales Channel

5.4.1 Ambulatory Surgical Centers

5.4.2 Hospitals

5.4.3 Other Sales Channels

5.5 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 F. Hoffmann-La Roche Ltd

6.1.2 Novartis AG

6.1.3 Pfizer Inc.

6.1.4 Panoptica

6.1.5 Bausch Health Companies Inc.

6.1.6 Regeneron Pharmaceuticals, Inc

6.1.7 Aerie Pharmaceutical Inc.

6.1.8 REGENXBIO Inc.

6.1.9 Bayer AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/zhg2a0